Targeting KRAS in Pancreatic Cancer
暂无分享,去创建一个
[1] He Huang,et al. Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting , 2022, Experimental Hematology & Oncology.
[2] A. Dingemans,et al. LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study , 2022, Annals of Oncology.
[3] Kwok-Kin Wong,et al. The current state of the art and future trends in RAS-targeted cancer therapies , 2022, Nature Reviews Clinical Oncology.
[4] Mallika Singh,et al. Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor , 2022, Cancer Research.
[5] K. Haigis,et al. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention. , 2022, Cancer discovery.
[6] T. Burns,et al. First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety , 2022, Journal of Clinical Oncology.
[7] J. Christensen,et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. , 2022, Journal of Clinical Oncology.
[8] N. Kraut,et al. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants , 2022, Cancer discovery.
[9] J. Blake,et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor. , 2021, Journal of medicinal chemistry.
[10] M. T. Beck,et al. KRAS is vulnerable to reversible switch-II pocket engagement in cells , 2021, bioRxiv.
[11] M. J. Chalmers,et al. Abstract 1259: Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor , 2021, Experimental and Molecular Therapeutics.
[12] P. Jänne,et al. Acquired Resistance to KRASG12C Inhibition in Cancer. , 2021, The New England journal of medicine.
[13] R. Govindan,et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.
[14] N. Kraut,et al. Targeting Son of Sevenless 1: The pacemaker of KRAS. , 2021, Current opinion in chemical biology.
[15] M. V. Vander Heiden,et al. The Metabolic Landscape of RAS-Driven Cancers from biology to therapy , 2021, Nature Cancer.
[16] C. Kiel,et al. The Ins and Outs of RAS Effector Complexes , 2021, Biomolecules.
[17] J. Smaill,et al. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. , 2020, Journal of medicinal chemistry.
[18] G. Fernandes,et al. Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases , 2020, Journal of Gastrointestinal Cancer.
[19] J. Johnston,et al. A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses , 2020, NPJ vaccines.
[20] T. Brummer,et al. Immune modulatory effects of oncogenic KRAS in cancer , 2020, Nature Communications.
[21] P. Hammerman,et al. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling , 2020, Clinical Cancer Research.
[22] S. Gottschalk,et al. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] L. Buday,et al. Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation , 2020, Cancer and Metastasis Reviews.
[24] R. Kortum,et al. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer , 2020, eLife.
[25] D. Unutmaz,et al. Mechanisms of T-Cell Exhaustion in Pancreatic Cancer , 2020, Cancers.
[26] F. McCormick,et al. RAS-targeted therapies: is the undruggable drugged? , 2020, Nature Reviews Drug Discovery.
[27] J. Blake,et al. Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer , 2020 .
[28] Raghu Kalluri,et al. The biology, function, and biomedical applications of exosomes , 2020, Science.
[29] N. Chen,et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. , 2019, Journal of medicinal chemistry.
[30] J. Desai,et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.
[31] D. V. Von Hoff,et al. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[32] J. Ross,et al. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. , 2019, Gastroenterology.
[33] Yijun Wang,et al. Targeting the untargetable KRAS in cancer therapy , 2019, Acta pharmaceutica Sinica. B.
[34] J. Yap,et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.
[35] H. Kocher,et al. Pancreatic Cancer , 2019, Methods in Molecular Biology.
[36] Oleksii S. Rukhlenko,et al. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. , 2018, Cell systems.
[37] P. Zarrinkar,et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.
[38] Kevan M. Shokat,et al. Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States. , 2017, Cell chemical biology.
[39] E. Collisson,et al. Advances in the Genetics and Biology of Pancreatic Cancer. , 2017, Cancer journal.
[40] Steven J. M. Jones,et al. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.
[41] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[42] P. Lyne,et al. Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS , 2017, Science Translational Medicine.
[43] P. Jänne,et al. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial , 2017, JAMA.
[44] Raghu Kalluri,et al. Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.
[45] P. Philip,et al. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial , 2017, JAMA oncology.
[46] J. Gartner,et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.
[47] Oleksii S. Rukhlenko,et al. MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. , 2016, Current opinion in structural biology.
[48] Ryan L. Kelly,et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.
[49] S. Steinberg,et al. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Yi Liu,et al. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. , 2016, Cancer discovery.
[51] Walter Kolch,et al. Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation , 2015, Angewandte Chemie.
[52] D. Torigian,et al. Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. , 2015 .
[53] R. Eliakim,et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients , 2015, Oncotarget.
[54] S. Fröhling,et al. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines , 2015, Scientific Reports.
[55] M. Kris,et al. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. , 2014, Clinical lung cancer.
[56] Ji Luo,et al. Development of siRNA payloads to target KRAS-mutant cancer. , 2014, Cancer discovery.
[57] Joon-Oh Park,et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.
[58] Gregory L. Szeto,et al. Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.
[59] Roland Seifert,et al. Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .
[60] Kevan M. Shokat,et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.
[61] Lincoln D. Stein,et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.
[62] H. Abken,et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. , 2012, Gastroenterology.
[63] Derek S. Chan,et al. The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.
[64] D. Bar-Sagi,et al. Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis , 2012, Nature Communications.
[65] T. Ciuleanu,et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy , 2012, Investigational New Drugs.
[66] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[67] S. Rosenberg,et al. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.
[68] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[69] R. Bernards,et al. Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.